GlassScriptPhysician profile
Robert R Lisek
NPI 1639187677
$6,151.03
in general payments reported to CMS, 2019-2025
39 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,617 · 2020: $271 · 2021: $899 · 2022: $620 · 2023: $1,035 · 2024: $970 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,743.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,164.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.83 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $687.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $623.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $371.37 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $347.04 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $282.48 | 2019-2025 | Spravato, Xarelto |
| Collegium Pharmaceutical, INC. | $166.11 | 2023-2025 | Nucynta, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.76 | 2019-2022 | |
| Abbvie INC. | $149.71 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $146.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $130.27 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $119.90 | 2019-2025 | Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $90.97 | 2019 | |
| Genentech USA, INC. | $90.06 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lisek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.